UPC APP 44530/2024

—·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Case details: Status
—
Action
Procedural application
Category
Other Procedural
Parties: Claimants
Alexion Pharmaceuticals, Inc.
Reps: Elena Hennecke (Freshfields Bruckhaus Deringer)
Respondents
Amgen Technology (Ireland) Unlimited Company
Amgen N.V.
Amgen GmbH (Germany)
Amgen GmbH (Austria)
Amgen AB
Amgen S.A.S.
Amgen s.r.l.
Amgen Biofarmacêutica Lda.
Amgen Zdravila D.O.O.
Reps: Tilman Müller-Stoy (Bardehle Pagenberg)
Division: Court of Appeal
Judges: Klaus Grabinski · President of the Court of Appeal and judge-rapporteur
Technology: Organic Chemistry
Language: —
First decided: Aug 8, 2024

Decisions

2024-08-08
Generic application
The Court of Appeal ruled that service of written pleadings must be effected through the Court's electronic CMS and that prior communication via Germany's beA (besonderes elektronisches Anwaltspostfach) does not constitute effective service under R.278.1 RoP.
Legal issues:Service of documentsR.278.1 RoPElectronic CMS servicebeA (besonderes elektronisches Anwaltspostfach)

Documents